Quick Answer
SpyGlass Pharma, Inc. reported Cash and Equivalents of $96.36 million for fiscal year 2025.
SpyGlass Pharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $96.36M | +492.3% |
| 2024 | $16.27M | — |
- SpyGlass Pharma, Inc. showed an increase of +492.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, SpyGlass Pharma, Inc.’s cash and equivalents has grown by 492.3% (from $16.27 million to $96.36 million).
- The most recent figure is from SpyGlass Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: